Nea
NEA describes a global venture capital platform investing across technology and healthcare from idea and seed stage through IPO, with early-stage and growth practices.
What stands out about Nea
NEA is a global venture capital firm founded in 1977 that invests across technology and healthcare, from incubation and seed through IPO. Its stated growth mandate includes investments of $50 million to $300 million or more, with possible minority investments, majority buyouts, recapitalizations, and other transaction types.[1][2][3][7][8]
What does Nea invest in?
New Enterprise Associates (NEA) is a global venture capital firm founded in 1977. The firm states that it helps entrepreneurs build businesses across multiple stages, sectors, and geographies.
NEA’s public materials describe support for founders from idea and seed stage through IPO, alongside investment across early-stage and growth opportunities.[1]
NEA states that it invests from incubation and seed through Series B through its early-stage fund, while its dedicated $3.2 billion growth fund targets Series C and later opportunities.
The firm’s stated growth mandate can include investments ranging from $50 million to $300 million or more. NEA also states that it can structure minority investments, majority buyouts, recapitalizations, and other transaction types.[2]
Owners comparing capital alternatives can review Auxo’s capital advisory services, valuation services, and full-versus-partial sale framework.
Published criteria: NEA reported more than $27 billion in assets under management as of December 31, 2024. Its growth-investment materials state that it can typically invest $50 million to $300 million or more and seek companies with scaled revenue typically greater than $25 million to $50 million, high retention, robust growth, durable unit economics, and platform potential.[2][3]
What should a business owner evaluate before taking capital from Nea?
Owners evaluating NEA should clarify which fund or affiliated vehicle would make the investment, whether the opportunity is being considered under the early-stage or growth strategy, and whether the proposed structure is a minority investment, majority buyout, recapitalization, or another transaction type. NEA publicly describes these separate stage practices and transaction structures.
For a growth opportunity, owners should also ask how NEA would apply its stated criteria regarding revenue scale, retention, growth, durable unit economics, commercialization, and platform potential.
Owners should confirm the proposed ownership percentage, governance rights, board representation, investor protections, follow-on capital, operating support, and expected liquidity pathways for the specific transaction. NEA’s public strategy disclosures do not establish those deal-specific terms.[2]
Which NEA fund or affiliated vehicle would make the investment, and is the opportunity being evaluated under the early-stage or growth strategy
What ownership percentage, governance rights, board representation, and investor protections would apply to the proposed investment
For a growth transaction, how would NEA evaluate revenue scale, retention, growth, durable unit economics, commercialization, and platform potential
What investment criteria does Nea publicly describe?
NEA focuses on companies in technology and healthcare. Its stated areas include enterprise and consumer technology, digital health, and life sciences.
For growth investments, NEA states that it seeks platform-potential companies with proven commercialization, scaled revenue typically greater than $25 million to $50 million, high retention, robust growth, and durable unit economics.[1][2]
NEA’s published growth criteria include proven commercialization, scaled revenue typically greater than $25 million to $50 million, high retention, robust growth, durable unit economics, and platform potential.
The applicable stage and transaction structure should be confirmed for a specific opportunity because NEA describes separate early-stage and growth investment practices and multiple possible transaction types.[2]
NEA describes itself as a global venture capital firm investing across geographies. Its current listed offices are in Menlo Park, New York, London, Timonium, and San Francisco.[4]
NEA’s official portfolio identifies Golden Analytics as a private technology and enterprise company first invested in during 2026 at the seed stage.
On September 25, 2025, NEA announced its lead investment in Factory’s $50 million Series B financing.
On July 23, 2024, NEA announced a US $500M+ investment in Clio and stated that it led Clio’s US $900M financing round.[2][5][6]
Recent public examples include NEA’s first investment in Golden Analytics, made in 2026 at the seed stage, its announced lead investment in Factory’s $50 million Series B financing on September 25, 2025, and its announced US $500M+ investment in Clio in connection with Clio’s US $900M financing round on July 23, 2024.[2][5][6]
What is not clear from Nea's public materials?
NEA’s official portfolio page states that the displayed portfolio companies are illustrative and do not purport to be a complete list of all NEA investments.
NEA’s official disclosures page states that investments for which the issuer has not provided permission to disclose publicly are excluded from the online investment list.[7][8]
Questions to ask before taking capital from Nea
Which NEA fund or affiliated vehicle would make the investment, and is the opportunity being evaluated under the early-stage or growth strategy?
What ownership percentage, governance rights, board representation, and investor protections would apply to the proposed investment?
For a growth transaction, how would NEA evaluate revenue scale, retention, growth, durable unit economics, commercialization, and platform potential?
What operating resources, follow-on capital, and expected liquidity pathways would be available for this specific opportunity?
Sources & research notes
- Official website / firm overview
- Investment strategy
- Transaction size / criteria
- Geography / market coverage
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Structure / regulatory context
- Public disclosure information
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.